Stryker Faces Shareholder Scrutiny After Disclosures of Lingering Peripheral Vascular Manufacturing Issues

Stryker’s (NYSE: SYK) share price suffered a sharp decline after the company disclosed ongoing manufacturing issues in its Peripheral Vascular business previously believed resolved.

Lingering Supply Chain Disruption Shakes Investor Confidence

On September 8, 2026, Stryker’s CFO revealed at the Wells Fargo Healthcare Conference that supply disruptions impacting its Peripheral Vascular segment would continue into fiscal Q4 2026. The issue had initially emerged during the company’s Q2 earnings on July 30, 2026, when a 6.7% decline in organic sales in the Peripheral Vascular unit and significant backlogs were disclosed. Management had originally expected the issues to be largely resolved by the end of Q3. The surprise continuation into Q4 triggered an intraday stock plunge of $26.70—or about 8.8%—wiping out over $10 billion in market value. National shareholder rights firm Hagens Berman has since opened an investigation into whether Stryker adequately disclosed the ongoing manufacturing challenges to investors. 

These details are consistent with market analysis indicating the stock declined approximately 15% between June 30 and October 1, largely driven by this segment disruption. That period also saw heavy insider selling, further weighing on sentiment. 

Setting the Stage: Q2 Performance and Prior Optimism

Earlier, on July 30, 2026, Stryker reported strong Q2 results: net sales rose 9.4% year-over-year to $6.6 billion, adjusted EPS jumped 17.9% to $3.69, beating consensus estimates by approximately 6–7%. Organic sales growth was similarly robust at 9%. The earnings beat came despite ongoing cybersecurity remediation efforts, which had previously disrupted plant operations. Management narrowed its full-year organic sales and EPS guidance, signaling confidence in the second-half recovery. 

However, the optimism was tempered shortly thereafter when supply chain issues in the Peripheral Vascular segment, specifically tied to the Inari acquisition, were revealed. The unresolved backlogs and lost sales undercut investor confidence, transforming what had been viewed as a stabilizing earnings recovery into persistent uncertainty. 

Importance for Investors: What to Watch Next

The unfolding situation raises immediate questions for investors ahead of Stryker’s upcoming third-quarter earnings release scheduled for October 29, 2026. Key items to monitor include:

• Whether management provides a clear resolution timeline for the Peripheral Vascular supply issues and quantifies the associated financial impact.
• The degree of market reaction to the Q3 results and the tone of forward commentary from management.
• Any updates regarding the shareholder investigation, including disclosures or corporate responses.
• Operational progress within other segments, such as MedSurg and Ortho, to assess offsetting growth potential amid Peripheral Vascular challenges.

Meanwhile, SYK shares were trading at $275.43 as of October 2, 2026, reflecting a slight intraday uptick of 0.82%, though still well below levels seen mid-year. 

Bottom Line

Stryker’s Q2 results initially signaled resilience after its cyberattack disruption, but renewed peripheral vascular supply setbacks have cast a shadow over its recovery story. The revelation of unresolved manufacturing problems and the resulting sell-off—amplified by legal scrutiny—marks a significant inflection point. With Q3 results due at the end of October, investors will be watching closely for signs of operational turnaround and transparent disclosure to regain confidence.